甲状腺间变性癌
甲状腺乳突癌
医学
癌症
甲状腺癌
癌症研究
免疫疗法
间质细胞
甲状腺
癌症免疫疗法
肿瘤微环境
滤泡细胞
滤泡状甲状腺癌
病理
内科学
肿瘤细胞
作者
Hao Peng,Weidong Ye,Pengcheng Yu,Licheng Tan,Xiao Shi,Xu-Feng Chen,Cong He,Jia‐Qian Hu,Wenjun Wei,Lu Zhang,Ning Qu,Wei Yu,Qinghai Ji,Dongmei Ji,Yulong Wang
出处
期刊:JCI insight
[American Society for Clinical Investigation]
日期:2024-03-07
标识
DOI:10.1172/jci.insight.173712
摘要
Both anaplastic thyroid cancer (ATC) and papillary thyroid cancer (PTC) originate from thyroid follicular epithelial cells, but ATC has a significantly worse prognosis and shows resistance to conventional therapies. However, clinical trials found that immunotherapy works better in ATC than late-stage PTC. Here, we utilized single-cell RNA sequencing (scRNA-seq) to generate a single-cell atlas of thyroid cancer. Differences in ATC and PTC tumor microenvironment (TME) components (including malignant cells, stromal cells, and immune cells) leading to the polarized prognoses were identified. Intriguingly, we found that CXCL13+ T lymphocytes were enriched in ATC samples and might promote the development of early tertiary lymphoid structure (TLS). Lastly, murine experiments and scRNA-seq analysis of a treated patient's tumor demonstrated that Famitinib plus anti-PD-1 antibody could advance TLS in thyroid cancer. Conclusively, we displayed the cellular landscape of ATC and PTC, finding that CXCL13+ T cells and early TLS might make ATC more sensitive to immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI